Terms and conditions
Registered Office: Unit 16 City Business Centre,
6 Brighton Road, Horsham,
West Sussex, RH13 5BB
Telephone: 01403 264898
VAT number: 333 2797 52
On June 18th 2018 the Scottish Health Minister, Shona Robison, announced a new access pathway for ‘ultra-orphan medicines’ in Scotland – medicines that can treat very rare conditions affecting fewer than 1 in 50,000 people.
This new development follows on from Dr Brian Montgomery’s Review of Access to New Medicines, published in December 2016, which noted a low approval rate for medicines for very rare conditions.
To resolve this, the report recommended the development of an alternative assessment pathway for ultra-orphan medicines. If a treatment meets the new definition of an ultra-orphan medicine and the Scottish Medicines Consortium (SMC) consider it clinically effective, then it will be made available via NHS Scotland for at least three years while information on its effectiveness is gathered.
The new pathway is scheduled to commence on October 1st 2018.Read more
Craig Bradley – PM Society Chairman, lead Market Access Interest Group and Brand Manager at Shire
Craig speaks about the Market Access Interest Group and upcoming event in June
Robert Whitemore – Market Access Interest Group member, Director, Roboleo & Cob>
Rob discusses the current Market Access challenges facing the industry
Hassan Chaudhury – Market Access Interest Group member, Chief Commercial Officer, Health iQ
Hassan talks about the importance of real world data